SPGM vs IEFA: Which Global Stock ETF Is the Better Buy?

The article compares two international equity ETFs and concludes that IEFA is the better buy for investors who already have U.S. exposure, thanks to its lower 0.07% expense ratio and higher 3.24% dividend yield versus SPGM’s 0.09% fee and 1.67% yield. SPGM has delivered stronger returns over the last 1-, 3-, 5-, and 10-year periods, with a 5-year growth of $1,688 vs. $1,457 for IEFA and a smaller max drawdown (25.9% vs. 30.4%). The piece is largely a comparative fund review rather than a market-moving catalyst.

Analysis

The headline trade is not “global vs developed ex-U.S.”; it is an implicit bet on whether U.S. mega-cap leadership keeps dominating foreign cyclicals. SPGM’s outperformance is heavily explained by its U.S. and tech tilt, so the fund has behaved like a diluted U.S. large-cap proxy rather than a true world diversification vehicle. That creates a second-order issue: investors using it for diversification may actually be concentrating factor exposure into AI/quality growth, which means the apparent risk reduction can disappear in a tech drawdown.

IEFA’s higher yield is less about generosity than about balance-sheet and payout regime differences abroad, which matters in a higher-for-longer world. If rates stay elevated, the relative appeal of cash distributions from non-U.S. banks, insurers, and industrials should remain supported, while long-duration growth valuation in SPGM remains more sensitive to multiple compression. That makes the current comparison a regime call: SPGM wins if U.S. earnings breadth re-accelerates; IEFA wins if U.S. leadership mean-reverts and global real rates stay sticky.

The key catalyst is not performance over the next few days but earnings dispersion over the next 2-3 quarters. If the dollar softens and global PMIs stabilize, IEFA should start to narrow the gap as exporters and financials get operating leverage. Conversely, if AI capex and buybacks keep concentrating returns in the same handful of U.S. names, SPGM can continue to look superior on a backward-looking basis even though it is offering less true geographic risk reduction.

Consensus is underestimating how much of SPGM’s advantage is path-dependent and how fragile it is to a rotation in market leadership. The trade-off is classic: pay slightly less for IEFA and get more income plus better diversification, or pay up for SPGM and own the already-crowded winners. In our view, the more interesting risk/reward is not owning SPGM outright, but using IEFA as the defensive international sleeve and only adding SPGM on a U.S. breadth breakout.

Key Decisions for Investors

• Rotate new international allocations into IEFA over SPGM for the next 3-6 months if the book already carries U.S. large-cap exposure; better diversification and yield with lower dependency on a continued U.S. megacap melt-up.
• Pair trade: long IEFA / short SPGM sized 1:1 for a 3-6 month relative-value view that leadership broadens beyond U.S. tech; risk is capped if AI/mega-cap momentum persists, so consider a stop if SPGM outperforms by ~5% from entry.
• If you want exposure to the same winners already embedded in SPGM, own NVDA/ASML directly rather than the basket; the ETF dilutes upside and hides concentration risk. Use a 1-2 quarter horizon and buy on market-wide pullbacks.
• Use IEFA as a hedge against a weaker-dollar / higher-for-longer regime: financials and industrials should benefit if global growth stabilizes while U.S. multiples compress. Favor a staggered entry over 2-4 weeks.
• Avoid initiating fresh SPGM in size unless U.S. breadth improves; the downside case is a factor unwind that can take 10-15% off the excess-return premium over one quarter while leaving the portfolio still heavily tied to the same crowded U.S. names.